Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467

Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

T Mazzulli 1, A E Simor 1, R Jaeger 1, S Fuller 1, D E Low 1
PMCID: PMC171616  PMID: 2334158

Abstract

The in vitro susceptibilities of 551 community isolates of Streptococcus pneumoniae from the Canadian province of Ontario to several new fluoroquinolones and beta-lactam antimicrobial agents were determined by a broth microdilution technique. Eight (1.5%) of these isolates were moderately susceptible (MICs, greater than or equal to 0.12 and less than or equal to 1.0 microgram/ml) to penicillin; none was resistant. Temafloxacin, ciprofloxacin, and ofloxacin (MICs for 90% of strains tested, between 1 and 2 micrograms/ml) were the most active fluoroquinolones tested, and BMY-28100 (MIC for 90% of strains tested, 0.25 microgram/ml) was the most active of the new beta-lactams tested.

Full text

PDF
468

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Spangler S. K., Crotty E., Jacobs M. R. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones. J Antimicrob Chemother. 1989 Apr;23(4):509–516. doi: 10.1093/jac/23.4.509. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol. 1987 Aug;6(4):367–377. doi: 10.1007/BF02013089. [DOI] [PubMed] [Google Scholar]
  3. Bacon A. P., Froome K., Gent A. E., Cooke T. K., Sowerby P. Lead poisoning from drinking soft water. Lancet. 1967 Feb 4;1(7484):264–266. doi: 10.1016/s0140-6736(67)91322-0. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Jones R. N. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother. 1989 Apr;23(4):527–535. doi: 10.1093/jac/23.4.527. [DOI] [PubMed] [Google Scholar]
  5. Dixon J. M., Lipinski A. E., Graham M. E. Detection and prevalence of pneumococci with increased resistance to penicillin. Can Med Assoc J. 1977 Nov 19;117(10):1159–1161. [PMC free article] [PubMed] [Google Scholar]
  6. Eggleston M., Park S. Y. Review of the 4-quinolones. Infect Control. 1987 Mar;8(3):119–125. doi: 10.1017/s0195941700067291. [DOI] [PubMed] [Google Scholar]
  7. Gombert M. E., Aulicino T. M. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin. Antimicrob Agents Chemother. 1984 Dec;26(6):933–934. doi: 10.1128/aac.26.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heifetz C. L., Bien P. A., Cohen M. A., Dombrowski M. E., Griffin T. J., Malta T. E., Sesnie J. C., Shapiro M. A., Wold S. A. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):29–42. doi: 10.1093/jac/21.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  10. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacobs M. R., Koornhof H. J., Robins-Browne R. M., Stevenson C. M., Vermaak Z. A., Freiman I., Miller G. B., Witcomb M. A., Isaäcson M., Ward J. I. Emergence of multiply resistant pneumococci. N Engl J Med. 1978 Oct 5;299(14):735–740. doi: 10.1056/NEJM197810052991402. [DOI] [PubMed] [Google Scholar]
  12. Jones R. N., Barry A. L. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother. 1988 Oct;32(10):1576–1582. doi: 10.1128/aac.32.10.1576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jorgensen J. H., Redding J. S., Maher L. A. Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins. Antimicrob Agents Chemother. 1988 Oct;32(10):1477–1480. doi: 10.1128/aac.32.10.1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Knapp C. C., Washington J. A., 2nd In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother. 1988 Jan;32(1):131–133. doi: 10.1128/aac.32.1.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leitner F., Pursiano T. A., Buck R. E., Tsai Y. H., Chisholm D. R., Misiek M., Desiderio J. V., Kessler R. E. BMY 28100, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Feb;31(2):238–243. doi: 10.1128/aac.31.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Phillips I., King A. Comparative activity of the 4-quinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S70–S76. doi: 10.1093/clinids/10.supplement_1.s70. [DOI] [PubMed] [Google Scholar]
  17. Van der Auwera P., Grenier P., Glupczynski Y., Pierard D. In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin. J Antimicrob Chemother. 1989 Feb;23(2):209–219. doi: 10.1093/jac/23.2.209. [DOI] [PubMed] [Google Scholar]
  18. Vellend H. Role of fluoroquinolones in lower respiratory tract infections. Clin Invest Med. 1989 Feb;12(1):39–43. [PubMed] [Google Scholar]
  19. Walker R. C., Wright A. J. Symposium on antimicrobial agents. The quinolones. Mayo Clin Proc. 1987 Nov;62(11):1007–1012. doi: 10.1016/s0025-6196(12)65073-3. [DOI] [PubMed] [Google Scholar]
  20. Ward J. Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects. Rev Infect Dis. 1981 Mar-Apr;3(2):254–266. doi: 10.1093/clinids/3.2.254. [DOI] [PubMed] [Google Scholar]
  21. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES